Two small phase II studies of sunitinib and pazopanib in mRCC also suggest a potential role for VEGF and the soluble forms of the VEGF receptor as predictive biomarkers; the first study found that significantly larger reductions in VEGF, sVEGFR-2 and sVEGFR-3 levels occurred in patients exhibiting an objective response to sunitinib, and in the second, decreases in sVEGFR-2 were significantly correlated with tumour response [112,124]. This evidence concerns the gene VEGFA and neoplasm.